Abstract
Objectives To estimate the absolute risk of cerebral venous thrombosis (CVT) and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19, and to assess the relative risks (RR) compared to influenza or the administration of an mRNA vaccine against COVID-19.
Design Retrospective cohort study based on an electronic health records network
Setting Linked records between primary and secondary care centres within 59 healthcare organisations, primarily in the USA
Participants All patients with a confirmed diagnosis of COVID-19 between January 20, 2020 and March 25, 2021 were included (N=537,913, mean [SD] age: 46.2 [21.4] years; 54.9% females). Cohorts (matched for age, sex, and race) of participants diagnosed with influenza (N=392,424) or receiving the BNT162b2 or mRNA-1273 vaccine (N=366,869) were used for comparison.
Main outcome measures Diagnosis of CVT (ICD-10 code I67.6) or PVT (ICD-10 code I81) within 2 weeks after a diagnosis of COVID-19.
Results The incidence of CVT after COVID-19 diagnosis was 42.8 per million people (95% CI 28.5–64.2) including 35.3 per million (95% CI 22.6–55.2) first diagnoses. This was significantly higher than the CVT incidence in a matched cohort of patients with influenza (RR=3.83, 95% CI 1.56–9.41, P<0.001) and people who received an mRNA vaccine (RR=6.67, 95% CI 1.98–22.43, P<0.001). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8–448.9) including 175.0 per million (95% CI 143.0–214.1) first diagnoses. This was significantly higher than the PVT incidence in a matched cohort of patients with influenza (RR=1.39, 95% CI 1.06–1.83, P=0.02) and people who received an mRNA vaccine (RR=7.40, 95% CI 4.87–11.24, P<0.001). Mortality after CVT and PVT was 17.4% and 19.9% respectively.
Conclusions The incidence of CVT and PVT is significantly increased after COVID-19. The data highlight the risk of serious thrombotic events in COVID-19 and can help contextualize the risks and benefits of vaccination in this regard.
What is known
‐ A systematic review of cohort studies suggested an incidence of CVT among hospitalised patients with COVID-19 to be about 800 per million patients. There was evidence of selection, ascertainment, and reporting bias in all included studies.
‐ The incidence of CVT and PVT among both hospitalised and non-hospitalised patients with COVID-19 is unknown.
‐ It is unknown if COVID-19 increases the risk of CVT and PVT.
What this study adds Our study estimates that the absolute risk of CVT and PVT are respectively 42.8 and 392.3 per million patients (both hospitalised and non-hospitalised) in the 2 weeks after a diagnosis of COVID-19. COVID-19 increases the risk of CVT and PVT compared to patients diagnosed with influenza, and to people who have received a COVID-19 mRNA vaccine.
Competing Interest Statement
SL is an employee of TriNetX. All other authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
NIHR Oxford Health Biomedical Research Centre (BRC-1215-20005). MT is an NIHR Academic Clinical Fellow. MH is a Wellcome Principal Research Fellow and supported by the NIHR Oxford Biomedical Research Centre. The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
TriNetX received a waiver from the Western Institutional Review Board (IRB) for all studies using their dataset given that they use formally anonymised and de-identifid data. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section 164.514(b)(1) of the HIPAA Privacy Rule, so that ethical approval from an institutional review board is not needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The TriNetX system returned the results of the analyses as .csv files, which were downloaded and archived. Data presented will be freely accessible at: [the URL will be added upon publication]. In addition, TriNetX will grant access to researchers if they have a specific concern (through a third-party agreement option).
